Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive a ...

Tenax Therapeutics Conference Call Summary Company Overview - **Company**: Tenax Therapeutics (NasdaqCM:TENX) - **Event**: 2026 Conference on March 10, 2026 - **Speakers**: Christopher Giordano (CEO), Stuart Rich (Chief Medical Officer) Key Points Industry and Product Focus - **Industry**: Pharmaceutical, specifically focusing on treatments for pulmonary hypertension and heart failure - **Product**: Oral levosimendan, aimed at treating patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) [1][2] Enrollment and Study Updates - **LEVEL Study Enrollment**: Achieved target of 230 PH-HFpEF patients randomized, completed ahead of schedule in approximately 2 years [2] - **Study Timeline**: Randomization expected to conclude in March, with results anticipated in the third quarter of 2026 [2] - **Patient Retention**: High retention rate in the trial, with over 90% of patients entering the open-label extension (OLE) phase [16][17] Financial Health - **Liquidity**: Improved liquidity since PIPE financing, with sufficient cash to fund operations for approximately 18 months beyond data readout [3] Mechanism of Action - **Mechanism**: Oral levosimendan works by redistributing blood volume from splanchnic circulation to the lungs, addressing the issue of pulmonary hypertension in PH-HFpEF patients [11][12] - **Clinical Evidence**: Previous trials (HELP) demonstrated that levosimendan effectively reduces right atrial pressure and pulmonary artery pressure while maintaining cardiac output [13][14] Patient Experience and Anecdotal Evidence - **Patient Feedback**: Patients report significant improvements in quality of life, with anecdotes of increased activity levels and ability to perform daily tasks [53] - **Placebo Effect Considerations**: Patient responses can vary based on their initial health status; sicker patients are less likely to improve on placebo [19] Statistical Analysis and Trial Design - **Sample Size Reassessment**: Adjusted sample size based on interim analysis, increasing the power of the study to over 90% [30][35] - **Expected Outcomes**: Targeting a 25-meter improvement in the six-minute walk test, which is considered clinically meaningful for this patient population [37] Global Expansion Plans - **Future Trials**: Plans for LEVEL Two trial with a larger footprint, aiming to recruit in multiple countries including the U.S., Europe, Korea, and Taiwan [57][58] - **Recruitment Strategy**: Leveraging existing relationships with pulmonary hypertension experts to enhance recruitment efforts [59] Regulatory Considerations - **FDA Interactions**: Ongoing discussions with regulatory experts regarding potential pathways for drug approval, including the possibility of rolling submissions based on safety data [69][70] Company Growth and Structure - **Workforce Expansion**: Tripled employee count since raising funds, focusing on building relationships with investigators and opinion leaders globally [73][75] - **Commercialization Strategy**: Preparing for global commercialization with a focus on pre-commercial relationship management and medical teams [75] Additional Insights - **Market Potential**: Approximately 80% of HFpEF patients may have pulmonary hypertension, indicating a significant market opportunity for oral levosimendan if approved [23][24] - **Patient Demographics**: LEVEL trial participants are less symptomatic compared to those in the HELP trial, which may influence treatment outcomes [22] This summary encapsulates the critical insights from the Tenax Therapeutics conference call, highlighting the company's advancements, study progress, and strategic plans within the pharmaceutical industry.

Clinical Trials and Development - The company is conducting two Phase 3 clinical trials for oral levosimendan, which are expected to be expensive and time-consuming[23] - The company is conducting two Phase 3 clinical trials, LEVEL and LEVEL-2, for oral levosimendan, which are both expensive and time-consuming[23] - The company requires substantial additional funding to further develop and commercialize its product candidates, including completing ongoing clinical trials[23] - The company expects to incur substantial additional funding needs to further develop and commercialize its product candidates, including completing ongoing clinical trials[23] - The company relies heavily on third parties for conducting nonclinical testing and clinical studies, which poses risks to product development timelines[26] - The company is dependent on third parties for conducting nonclinical testing and clinical studies, which poses risks to the development of its product candidates[26] Financial Performance and Profitability - The company has incurred losses since inception and expects to continue incurring losses in the foreseeable future, with no guarantee of ever becoming profitable[24] - The company has incurred losses since inception and expects to continue incurring losses in the foreseeable future[24] - The company expects its operating results to fluctuate on a quarterly and annual basis, making future performance difficult to predict[23] - The company may be required to make milestone and royalty payments related to the levosimendan intellectual property, affecting profitability if approved[23] Market and Competition - The market acceptance of the company's products remains uncertain, which could impact future revenue generation[23] - The market acceptance of the company's products remains uncertain, which could impact future revenue[23] - The company may face significant competition that could render its product candidates noncompetitive or obsolete[29] - The company may face significant competition that could render its product candidates noncompetitive or obsolete[29] Regulatory and Commercialization Challenges - The company is subject to extensive government regulation, which is difficult to predict and could delay or prevent product commercialization[29] - The company is subject to extensive government regulation, which is difficult to predict and could delay product approval[29] - The company has limited marketing capabilities and no sales organization, which may hinder successful commercialization of its products if approved[23] - The company has limited marketing capabilities and no sales organization, which could hinder successful commercialization of its products[26] - The company currently has no approved drug products for sale and cannot guarantee future marketable drug products[23] - The company may incur substantial liabilities from product liability lawsuits, which could limit commercialization efforts[29]

Financial Results Announcement - Tenax Therapeutics, Inc. announced its financial results for Q4 and full year ended December 31, 2025, on March 10, 2026[4] - The press release detailing the financial results is attached as Exhibit 99.1[4] Company Information - The company is listed on The Nasdaq Stock Market under the trading symbol TENX[4] - The report does not indicate whether Tenax Therapeutics is an emerging growth company[4] Regulatory Information - The financial results will not be deemed "filed" under the Securities Exchange Act of 1934[5]

Corporate Presentation March 2026 Forward-Looking Statements Disclaimers Except for historical information, all of the statements, expectations and assumptions contained in this presentation are forward-looking statements. These forward-looking statements may include information concerning possible or projected future business operations. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ mater ...

Core Insights - Tenax Therapeutics has achieved its randomization target of 230 patients in the Phase 3 LEVEL study, with topline data expected in the third quarter of 2026 [2][6] - The company has initiated the global Phase 3 LEVEL-2 clinical trial and opened a long-term open-label extension study for patients to continue receiving the drug [1][2] Recent Corporate and Clinical Highlights - The screening period for the LEVEL study has closed, and randomization is anticipated to be completed by the end of March 2026 [2][6] - Tenax is focused on activating clinical sites globally for the LEVEL-2 study, which is expected to complete enrollment by the end of 2027 [2][6] - A virtual call with key opinion leaders was held in November 2025 to discuss the treatment landscape for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) [6] - In December 2025, a prespecified Blinded Sample Size Re-estimation (BSSR) demonstrated that the LEVEL study is powered at over 90% to detect a 25-meter change in 6-minute walk distance [6] Financial Results - As of December 31, 2025, Tenax reported cash and cash equivalents of $97.6 million, expected to fund operations through 2027 [4] - Research and development (R&D) expenses for Q4 2025 were $10.5 million, up from $4.6 million in Q4 2024, with total R&D expenses for the year at $32.7 million compared to $12.7 million in 2024 [5][7] - General and administrative (G&A) expenses for Q4 2025 were $5.9 million, compared to $2.7 million in Q4 2024, with total G&A expenses for the year at $23.7 million versus $6.8 million in 2024 [8] - The net loss for Q4 2025 was $15.5 million, compared to a net loss of $6.3 million in Q4 2024, with a total net loss for the year of $52.6 million compared to $17.6 million in 2024 [9][18]

Group 1 - Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing novel cardiopulmonary therapies [1][3] - The company will participate in the 2026 Leerink Partners Global Healthcare Conference from March 8-11, 2026, in Miami, FL [1] - The presentation will be a fireside chat featuring key executives, including the President & CEO, Chief Medical Officer, and Chief Business Officer, scheduled for March 10, 2026, at 2:20 p.m. ET [2] Group 2 - Tenax Therapeutics owns global rights to develop and commercialize levosimendan, targeting the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension, for which no product has been approved to date [3]

Tenax Therapeutics Conference Call Summary Company Overview - **Company**: Tenax Therapeutics (NasdaqCM:TENX) - **Focus**: Development of levosimendan for heart failure patients with pulmonary hypertension (PH-HFpEF) [4][3] Key Points and Arguments Clinical Trials and Development - **Phase 3 Trial**: Initiated a global Phase 3 trial of levosimendan in heart failure patients with PH, with a recruitment period expected to last two years [4][5] - **First Trial**: Nearing completion of recruitment for a Phase 2 trial in the US and Canada, targeting 230 randomized subjects, with data expected in the second half of the year [4][5] - **Unique Aspects of LEVEL Study**: The LEVEL study tested invasive hemodynamics under exercise conditions, which is unprecedented in this patient population [23][25] Market Opportunity - **Market Size**: Estimated multi-billion dollar commercial opportunity, with over 2 million patients in the US and a similar number in Europe suffering from PH-HFpEF, and no approved therapies available [14][12] - **Intellectual Property**: Strong IP position for levosimendan in treating PH-HFpEF enhances commercial potential [14][12] Drug Mechanism and Efficacy - **Mechanism of Action**: Levosimendan acts as a vasodilator, reducing preload in patients, which is crucial for those with elevated wedge pressure [8][11] - **Clinical Outcomes**: In the Phase 2 trial, patients showed a 29-meter improvement in the six-minute walk test and significant reductions in wedge pressure without changes in cardiac output [11][11] Patient Recruitment and Study Design - **Patient Cohorts**: The trial is recruiting a broad cohort, including both Cpc-PH and Ipc-PH phenotypes, which allows for a larger patient population [17][19] - **Study Duration**: The upcoming trial will last 26 weeks, compared to 12 weeks for the previous study, allowing for more comprehensive data collection [61][63] Safety and Compliance - **Open-Label Extension (OLE)**: Patients transitioning from IV to oral levosimendan showed high acceptance, with 18 out of 19 agreeing to switch to the oral formulation [35][39] - **Patient Feedback**: Positive anecdotal feedback from patients regarding the oral formulation, with improvements noted in KCCQ scores and BNP levels [45][41] Competitive Landscape - **Differentiation**: Tenax's product profile is distinct from competitors, with demonstrated improvements in six-minute walk distance and exercise hemodynamics, and an oral therapy option compared to subcutaneous alternatives [110][112] - **Market Position**: The company believes it has a strong competitive edge due to its broader patient recruitment strategy and unique drug delivery method [112][110] Additional Important Information - **Regulatory Considerations**: The FDA values symptom-addressing data, which could support approval based on KCCQ improvements, although the primary endpoint remains the six-minute walk test [29][32] - **Adaptive Trial Design**: The company implemented a blinded sample size reassessment to ensure adequate power for detecting meaningful changes in the primary endpoint [64][66] This summary encapsulates the critical insights from the Tenax Therapeutics conference call, highlighting the company's strategic direction, market potential, and clinical development efforts.

Core Viewpoint - Tenax Therapeutics, Inc. will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its focus on developing novel cardiopulmonary therapies [1]. Company Overview - Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company specializing in cardiopulmonary therapies [3]. - The company holds global rights to develop and commercialize levosimendan, targeting PH-HFpEF, the most common form of pulmonary hypertension, for which no product has been approved to date [3]. - Tenax Therapeutics is publicly traded on The Nasdaq Stock Market under the symbol "TENX" [3]. Event Details - The fireside chat will feature Chris Giordano, President & CEO, and Douglas Randall, Chief Business Officer [2]. - The event is scheduled for February 11, 2026, at 12:30 p.m. ET [2]. - A live and archived webcast of the presentation will be available on the company's investor relations webpage [2].

分组1 - The article emphasizes the importance of careful fundamental analysis in identifying potential high-return investments, particularly in the small- and mid-cap sectors [1] - The focus is on early-commercial-stage life sciences companies, insurers, homebuilders, and select consumer-facing businesses, indicating a targeted investment strategy [1] - The author avoids investment opportunities that cannot be intelligently analyzed, highlighting a disciplined approach to investment selection [1] 分组2 - The article does not provide any specific financial data or performance metrics related to the companies or sectors discussed [2][3]